Hypogonadism and erectile dysfunction: Pathophysiological observations and therapeutic outcomes

BJU International

Volumn 92, Issue 9, 2003, Pages 896-899

  Morales, A ^a   Heaton, J P W ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Androgens; Hypogonadism; Pathophysiology; Sexual dysfunction; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ESTRADIOL; PRASTERONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

CLINICAL FEATURE; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; HYPOGONADISM; LIBIDO; MENTAL CAPACITY; MUSCLE STRENGTH; OSTEOPOROSIS; PATHOPHYSIOLOGY; PENIS ERECTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SHORT SURVEY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; WELLBEING;

ANDROGENS; HUMANS; HYPOGONADISM; IMPOTENCE; MALE;

EID: 0345734380     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04532.x     Document Type: Short Survey

References (24)

1. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-56
2. Sato Y, Shibuya A, Adachi H et al. Restoration of sexual behavior and dopaminergic neurotransmission by long term exogenous testosterone replacement in aged male rats. J Urol 1998; 160: 1572-
3. Park KH, Kim SW, Kim KD et al. Effect of androgen on the expression of nitric oxide synthase (NOS) isoform of mRNAs in the penile corpus cavernosus of castrated rats. BJU Int 1999; 83: 327-33
4. Aversa A, Isidori AM, De Martino MU et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol 2000; 54: 517-23
5. Ferrini M, Wang C, Swerdloff RS et al. Age related increased expression of inducible nitric oxide synthase and cytotoxic markers in rat hypothalamic regions associated with male reproductive function. Neuroendocrinology 2000; 74: 1-9
6. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Testosterone therapy converts sildenafil non-responders to responders in men with hypogonadism and erectile dysfunction who failed prior sildenafil therapy. J Urol 2003; 169: 247 (Abstract)
7. Aversa A, Isidori AM, Spera G et al. Androgens improve cavernous dilatation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003; 59: 632-8
8. Kalinchenko SY, Kozlov GI, Gontcharov NP et al. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6: 94-9
9. Feldman HA, Goldstein I, Hartzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
10. Vermeulen A. Andropause. Maturitas 2000; 34: 5-11
11. Reiter WJ, Pycha A, Schatzl G et al. Serum dehydroepiandrosterone sulfate concentration in men with erectile dysfunction. Urology 2000; 55: 755-81
12. Greenstein A, Plymate SR, Katz PG. Visually stimulated erection in castrated men. J Urol 1995; 153: 650-2
13. Morales A, Johnston B, Heaton JPW, Lundie M. Testosterone supplementation in hypogonadal impotence, assessment of biochemical measurements and therapeutic outcomes. J Urol 1997; 157: 849-54
14. Nieschlag E, Behere HM. Pharmacological and clinical uses of testosterone. In Nieschlar A, Behere HM eds, Testosterone: Action, Deficiency and Substitution. Berlin: Springer-Verlag, 1998: 294-321
15. Carani C, Granata AR, Bancroft J et al. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 1995; 20: 743-50
16. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of the International Society for the Study of the Aging Male. Aging Male 2002; 5: 74-86
17. Morley JE, Ping P, Perry HM III. Evaluation of assays available to measure free testosterone. Metabolism 2002; 51: 554-9
18. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction, clinical significance and cost-effective strategy. J Urol 1997; 158: 1764-7
19. Garg RK, Khaishgi A, Dandona P. Is management with sildenafil changing clinical practice? Lancet 1999; 353: 375
20. Brien SE, Heaton JP, Racz WJ et al. Effects of an environmental antiandrogen on erectile function in an animal penile erection model. J Urol 2000; 163: 1315
21. Negro-Vilar A. Selective androgen receptor modulators (SARMs). a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999; 84: 3459
22. Morales A, Johnston B, Heaton JWP, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994; 152: 1115-9
23. Wang C, Swerdloff RS. Should the non-aromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab 2002; 87: 1462-6
24. Artl W, Callies F, Koehler I et al. Dehydroepiandrosterone supplementation in healthy men with age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001; 86: 4686-92